• 22 MAR 2022

    PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed a 24-month product stability study required by the U.S. Food and Drug Administration (FDA) for its clinical trial product candidate, CypCaps™. The

    Read more →
    • 16 MAR 2022

    PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

    LAS VEGAS, NV, March 16, 2022 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial and operational results for its third quarter ended January 31, 2022, and provided an overview of recent operational

    Read more →
    • 22 FEB 2022

    PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the results of an additional, more finely detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that

    Read more →
    • 14 FEB 2022

    PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

    LAS VEGAS, NV February 14, 2022 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update on PharmaCyte’s activities to lift the U.S. Food and Drug Administration’s (FDA) clinical hold on PharmaCyte’s treatment for

    Read more →
    • 06 JAN 2022

    PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The Conference is being held virtually on January 10-13, 2022. During

    Read more →
    • 04 JAN 2022

    PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the empty capsule material that makes up PharmaCyte’s CypCaps® pancreatic cancer product candidate is not toxic for the encapsulated cells inside the CypCaps. PharmaCyte’s Chief Executive

    Read more →
    • 28 DEC 2021

    PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a 36-month stability study of the cells from its Master Cell Bank (MCB). These cells will be encapsulated and then used

    Read more →
    • 15 DEC 2021

    PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

    LAS VEGAS–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial results for its second quarter ended October 31, 2021, and provided an overview of recent operational highlights (PharmaCyte’s Fiscal Year begins May 1 and ends

    Read more →
    • 08 DEC 2021

    PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

    LAGUNA HILLS, CA, December 8, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of an additional, more detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the

    Read more →
    • 30 NOV 2021

    PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

    LAS VEGAS, November 30, 2021–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the commencement of a pivotal study to determine if the treatment PharmaCyte uses for locally

    Read more →